Abacavir Sulfate

CHEMBL4303288 Phase 4 Approved Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

670.7 g/mol

LogP

—

Phase

4

The sulfate salt of abacavir carries the same antiretroviral activity and the same precautions as the parent nucleoside analogue, and is the form used in oral combination regimens for HIV infection. It is never given alone; treatment pairs it with other antiretroviral agents to suppress viral replication and limit the emergence of resistance. The defining safety consideration is genetic: carriage of the HLA-B*5701 allele predicts a hypersensitivity reaction that can be life-threatening, so screening for that variant precedes any exposure to the drug. This pharmacogenomic screening requirement is one of the earliest routine examples in antiretroviral practice. The salt has the formula C28H38N12O6S, a mass close to 670.7 g/mol, and is an approved small molecule.

The sulfate salt form of abacavir, an antiretroviral medicine used to treat HIV infection with the same mechanism and precautions as abacavir itself. It is taken orally, usually once or twice daily as part of a combination HIV therapy regimen. Patients should be screened for the HLA-B*5701 gene variant before starting treatment to avoid a potentially life-threatening hypersensitivity reaction.

Molecular Weight

670.7000 g/mol

TPSA

287.00 Å²

Therapeutic Areas

HIV/AIDS

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Structure

SVG PNG

Cite this structure

Embed this structure

SMILES

Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1.Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1.O=S(=O)(O)O

InChI

InChI=1S/2C14H18N6O.H2O4S/c2*15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-21;1-5(2,3)4/h2*1,4,7-10,21H,2-3,5-6H2,(H3,15,17,18,19);(H2,1,2,3,4)/t2*8-,10+;/m11./s1

Molecular Formula

C28H38N12O6S

HBD / HBA

8 / 16

Rotatable Bonds

8

Heavy Atoms

47

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

The sulfate salt form of abacavir, an antiretroviral medicine used to treat HIV infection with the same mechanism and precautions as abacavir itself. It is taken orally, usually once or twice daily as part of a combination HIV therapy regimen. Patients should be screened for the HLA-B*5701 gene variant before starting treatment to avoid a potentially life-threatening hypersensitivity reaction.

Yes, Abacavir Sulfate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4303288. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 441384. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

PillFYI

Looking for patient-friendly information?

Abacavir Sulfate on PillFYI

Structure

Quick Data

Formula: C28H38N12O6S
Synonyms: 4

External Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.